The biosimulation market size has grown rapidly in recent years. It will grow from $4.98 billion in 2025 to $5.84 billion in 2026 at a compound annual growth rate (CAGR) of 17.3%. The growth in the historic period can be attributed to growth in pharmaceutical R&D activities, increasing complexity of biological systems research, adoption of computational modeling in drug development, rising regulatory acceptance of simulation data, availability of advanced computing resources.
The biosimulation market size is expected to see rapid growth in the next few years. It will grow to $11.11 billion in 2030 at a compound annual growth rate (CAGR) of 17.5%. The growth in the forecast period can be attributed to increasing demand for precision medicine modeling, rising investments in AI-driven biosimulation tools, expansion of in silico clinical trials, growing focus on reducing drug development timelines, increasing adoption of cloud-based biosimulation platforms. Major trends in the forecast period include increasing adoption of model-based drug development, rising use of pk and pd simulation platforms, growing integration of virtual clinical trials, expansion of disease modeling applications, enhanced focus on predictive toxicology modeling.
The global rise in healthcare expenditure is anticipated to support the expansion of the biosimulation market over the forecast period. Healthcare expenditure represents the total financial resources allocated to healthcare goods and services, including drug development, clinical trials, and medical technologies. Increasing healthcare spending is driven by growing demand for advanced medical treatments, aging populations, and rising investment in innovative drug development. The biosimulation market directly benefits from this trend, as higher spending accelerates the adoption of computational modeling and simulation tools that facilitate virtual clinical trials and predictive disease modeling for drug development. For instance, in April 2025, the American Medical Association, a US-based national professional association, reported that healthcare spending reached US$ 4.87 trillion in 2023, marking a 7.5% year-on-year increase, equivalent to approximately US$ 14,570 per person. Therefore, the global increase in healthcare expenditure is driving the growth of the biosimulation market.
Major companies operating in the biosimulation market are prioritizing the development of advanced solutions, such as integrated pharmacokinetic-pharmacodynamic (PK-PD) modeling platforms, to improve drug development efficiency, enhance predictive accuracy, and accelerate therapeutic decision-making. Integrated PK-PD modeling platforms are software systems that simulate drug behavior and effects in virtual populations, enabling researchers to optimize dosing strategies, anticipate outcomes, and reduce dependence on costly clinical trials. For example, in August 2024, Certara, Inc., a US-based biosimulation and drug development company, introduced Phoenix version 8.5, an upgraded platform designed to streamline PK-PD modeling, population simulations, and clinical trial forecasting. The platform offers improved data analysis, enhanced visualization features, and scenario testing to support better decision-making throughout the drug development process. By leveraging these biosimulation advancements, the initiative enables faster, safer, and more cost-efficient development of new therapies while optimizing clinical study design.
In January 2023, Certara, Inc., a US-based provider of biosimulation software, technology, and services for drug discovery and development, acquired Vyasa Analytics, LLC for an undisclosed amount. Through this acquisition, Certara intends to enhance its software capabilities by incorporating deep learning and data fabric technologies into its biosimulation portfolio. Vyasa Analytics is a US-based company that offers biosimulation-related solutions through its advanced AI and deep-learning software platform.
Major companies operating in the biosimulation market are Certara Inc.; Dassault Systèmes SE; Schrödinger Inc.; Simulations Plus Inc.; Rhenovia Pharma SAS; Insilico Biotechnology AG; Genedata AG; Entelos Inc.; Physiomics plc; Rosa & Co. LLC.; In Silico Biosciences Inc.; INOSIM Software GmbH; LeadInvent Technologies Limited; Nuventra Pharma Sciences Inc.; Archimedes Inc.; VeriSIM Life Inc.; Compugen Inc.; Leadscope Inc.; Pharmaceutical Product Development LLC; Advanced Chemistry Development Inc.; Chemical Computing Group Inc.; Immunetrics and PPD Inc.; Instem India Private Limited; Evidera Inc.; Biomodels LLC; PhysioStim SA; Lhasa Limited; SimBioSys Inc.; Cadence Design Systems Inc.; Allucent Inc.
North America was the largest region in the biosimulation market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biosimulation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biosimulation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the biosimulation market by increasing costs of imported high-performance computing hardware, specialized software tools, data storage infrastructure, and analytical platforms used in complex biological modeling. Pharmaceutical and biotechnology companies in North America and Europe are most affected due to reliance on advanced imported computing systems, while Asia-Pacific faces higher costs for software licensing and infrastructure expansion. These tariffs are increasing operational expenses and slowing platform upgrades. However, they are also encouraging local software development, regional cloud infrastructure investments, and greater adoption of cost-efficient simulation-as-a-service models.
The biosimulation market research report is one of a series of new reports that provides biosimulation market statistics, including biosimulation industry global market size, regional shares, competitors with a biosimulation market share, detailed biosimulation market segments, market trends and opportunities, and any further data you may need to thrive in the biosimulation industry. This biosimulation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Biosimulation is a mathematical simulation process that uses computers to replicate biological processes and systems. The aim of biosimulation is a model-based prediction of the dynamics and behavior of biological systems.
The main types of products in the biosimulation market are software and services. The biosimulation software provides software for molecular modelling and simulation, pharmacokinetic/pharmacodynamic (PK/PD) modelling and simulation, toxicity prediction software, physiologically based pharmacokinetic modeling, and simulation (PBPK) modelling and simulation, trial design software, and others. It is used in drug development, drug discovery, and others and implemented in various verticals such as pharmaceutical and biotechnology companies, contract research organizations (CROs), regulatory authorities, academic research institutions, others.
The biostimulation market includes revenues earned by entities by providing stimulation technology that provide simulations of biological processes and predict the behavior of biological systems to enhance the research and development (R&D) process. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The biosimulation market size is expected to see rapid growth in the next few years. It will grow to $11.11 billion in 2030 at a compound annual growth rate (CAGR) of 17.5%. The growth in the forecast period can be attributed to increasing demand for precision medicine modeling, rising investments in AI-driven biosimulation tools, expansion of in silico clinical trials, growing focus on reducing drug development timelines, increasing adoption of cloud-based biosimulation platforms. Major trends in the forecast period include increasing adoption of model-based drug development, rising use of pk and pd simulation platforms, growing integration of virtual clinical trials, expansion of disease modeling applications, enhanced focus on predictive toxicology modeling.
The global rise in healthcare expenditure is anticipated to support the expansion of the biosimulation market over the forecast period. Healthcare expenditure represents the total financial resources allocated to healthcare goods and services, including drug development, clinical trials, and medical technologies. Increasing healthcare spending is driven by growing demand for advanced medical treatments, aging populations, and rising investment in innovative drug development. The biosimulation market directly benefits from this trend, as higher spending accelerates the adoption of computational modeling and simulation tools that facilitate virtual clinical trials and predictive disease modeling for drug development. For instance, in April 2025, the American Medical Association, a US-based national professional association, reported that healthcare spending reached US$ 4.87 trillion in 2023, marking a 7.5% year-on-year increase, equivalent to approximately US$ 14,570 per person. Therefore, the global increase in healthcare expenditure is driving the growth of the biosimulation market.
Major companies operating in the biosimulation market are prioritizing the development of advanced solutions, such as integrated pharmacokinetic-pharmacodynamic (PK-PD) modeling platforms, to improve drug development efficiency, enhance predictive accuracy, and accelerate therapeutic decision-making. Integrated PK-PD modeling platforms are software systems that simulate drug behavior and effects in virtual populations, enabling researchers to optimize dosing strategies, anticipate outcomes, and reduce dependence on costly clinical trials. For example, in August 2024, Certara, Inc., a US-based biosimulation and drug development company, introduced Phoenix version 8.5, an upgraded platform designed to streamline PK-PD modeling, population simulations, and clinical trial forecasting. The platform offers improved data analysis, enhanced visualization features, and scenario testing to support better decision-making throughout the drug development process. By leveraging these biosimulation advancements, the initiative enables faster, safer, and more cost-efficient development of new therapies while optimizing clinical study design.
In January 2023, Certara, Inc., a US-based provider of biosimulation software, technology, and services for drug discovery and development, acquired Vyasa Analytics, LLC for an undisclosed amount. Through this acquisition, Certara intends to enhance its software capabilities by incorporating deep learning and data fabric technologies into its biosimulation portfolio. Vyasa Analytics is a US-based company that offers biosimulation-related solutions through its advanced AI and deep-learning software platform.
Major companies operating in the biosimulation market are Certara Inc.; Dassault Systèmes SE; Schrödinger Inc.; Simulations Plus Inc.; Rhenovia Pharma SAS; Insilico Biotechnology AG; Genedata AG; Entelos Inc.; Physiomics plc; Rosa & Co. LLC.; In Silico Biosciences Inc.; INOSIM Software GmbH; LeadInvent Technologies Limited; Nuventra Pharma Sciences Inc.; Archimedes Inc.; VeriSIM Life Inc.; Compugen Inc.; Leadscope Inc.; Pharmaceutical Product Development LLC; Advanced Chemistry Development Inc.; Chemical Computing Group Inc.; Immunetrics and PPD Inc.; Instem India Private Limited; Evidera Inc.; Biomodels LLC; PhysioStim SA; Lhasa Limited; SimBioSys Inc.; Cadence Design Systems Inc.; Allucent Inc.
North America was the largest region in the biosimulation market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biosimulation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biosimulation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the biosimulation market by increasing costs of imported high-performance computing hardware, specialized software tools, data storage infrastructure, and analytical platforms used in complex biological modeling. Pharmaceutical and biotechnology companies in North America and Europe are most affected due to reliance on advanced imported computing systems, while Asia-Pacific faces higher costs for software licensing and infrastructure expansion. These tariffs are increasing operational expenses and slowing platform upgrades. However, they are also encouraging local software development, regional cloud infrastructure investments, and greater adoption of cost-efficient simulation-as-a-service models.
The biosimulation market research report is one of a series of new reports that provides biosimulation market statistics, including biosimulation industry global market size, regional shares, competitors with a biosimulation market share, detailed biosimulation market segments, market trends and opportunities, and any further data you may need to thrive in the biosimulation industry. This biosimulation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Biosimulation is a mathematical simulation process that uses computers to replicate biological processes and systems. The aim of biosimulation is a model-based prediction of the dynamics and behavior of biological systems.
The main types of products in the biosimulation market are software and services. The biosimulation software provides software for molecular modelling and simulation, pharmacokinetic/pharmacodynamic (PK/PD) modelling and simulation, toxicity prediction software, physiologically based pharmacokinetic modeling, and simulation (PBPK) modelling and simulation, trial design software, and others. It is used in drug development, drug discovery, and others and implemented in various verticals such as pharmaceutical and biotechnology companies, contract research organizations (CROs), regulatory authorities, academic research institutions, others.
The biostimulation market includes revenues earned by entities by providing stimulation technology that provide simulations of biological processes and predict the behavior of biological systems to enhance the research and development (R&D) process. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Biosimulation Market Characteristics
3. Biosimulation Market Supply Chain Analysis
4. Global Biosimulation Market Trends and Strategies
5. Biosimulation Market Analysis of End Use Industries
7. Global Biosimulation Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Biosimulation Total Addressable Market (TAM) Analysis for the Market
9. Biosimulation Market Segmentation
10. Biosimulation Market, Industry Metrics by Country
11. Biosimulation Market Regional and Country Analysis
12. Asia-Pacific Biosimulation Market
13. China Biosimulation Market
14. India Biosimulation Market
15. Japan Biosimulation Market
16. Australia Biosimulation Market
17. Indonesia Biosimulation Market
18. South Korea Biosimulation Market
19. Taiwan Biosimulation Market
20. South East Asia Biosimulation Market
21. Western Europe Biosimulation Market
22. UK Biosimulation Market
23. Germany Biosimulation Market
24. France Biosimulation Market
25. Italy Biosimulation Market
26. Spain Biosimulation Market
27. Eastern Europe Biosimulation Market
28. Russia Biosimulation Market
29. North America Biosimulation Market
30. USA Biosimulation Market
31. Canada Biosimulation Market
32. South America Biosimulation Market
33. Brazil Biosimulation Market
34. Middle East Biosimulation Market
35. Africa Biosimulation Market
37. Biosimulation Market Competitive Landscape and Company Profiles
38. Biosimulation Market Other Major and Innovative Companies
41. Biosimulation Market High Potential Countries, Segments and Strategies
42. Appendix
Executive Summary
Biosimulation Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses biosimulation market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for biosimulation? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The biosimulation market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product: Software; Services2) By Application: Drug Development; Drug Discovery; Other Applications
3) By End User: Pharmaceutical And Biotechnology Companies; Contract Research Organizations (CROs); Academic Research Institutions; Other End Users
Subsegments:
1) By Software: Pharmacokinetics (PK) Simulation Software; Pharmacodynamics (PD) Simulation Software; Toxicology Simulation Software; Disease Modeling Software; Integrated Biosimulation Platforms2) By Services: Consulting Services; Model Development Services; Data Analysis And Interpretation Services; Training And Support Services; Custom Simulation Services
Companies Mentioned: Certara Inc.; Dassault Systèmes SE; Schrödinger Inc.; Simulations Plus Inc.; Rhenovia Pharma SAS; Insilico Biotechnology AG; Genedata AG; Entelos Inc.; Physiomics plc; Rosa & Co. LLC.; In Silico Biosciences Inc.; INOSIM Software GmbH; LeadInvent Technologies Limited; Nuventra Pharma Sciences Inc.; Archimedes Inc.; VeriSIM Life Inc.; Compugen Inc.; Leadscope Inc.; Pharmaceutical Product Development LLC; Advanced Chemistry Development Inc.; Chemical Computing Group Inc.; Immunetrics and PPD Inc.; Instem India Private Limited; Evidera Inc.; Biomodels LLC; PhysioStim SA; Lhasa Limited; SimBioSys Inc.; Cadence Design Systems Inc.; Allucent Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Biosimulation market report include:- Certara Inc.
- Dassault Systèmes SE
- Schrödinger Inc.
- Simulations Plus Inc.
- Rhenovia Pharma SAS
- Insilico Biotechnology AG
- Genedata AG
- Entelos Inc.
- Physiomics plc
- Rosa & Co. LLC.
- In Silico Biosciences Inc.
- INOSIM Software GmbH
- LeadInvent Technologies Limited
- Nuventra Pharma Sciences Inc.
- Archimedes Inc.
- VeriSIM Life Inc.
- Compugen Inc.
- Leadscope Inc.
- Pharmaceutical Product Development LLC
- Advanced Chemistry Development Inc.
- Chemical Computing Group Inc.
- Immunetrics and PPD Inc.
- Instem India Private Limited
- Evidera Inc.
- Biomodels LLC
- PhysioStim SA
- Lhasa Limited
- SimBioSys Inc.
- Cadence Design Systems Inc.
- Allucent Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 5.84 Billion |
| Forecasted Market Value ( USD | $ 11.11 Billion |
| Compound Annual Growth Rate | 17.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 31 |
